Long noncoding RNA ZFAS1 enhances adriamycin resistance in pediatric acute myeloid leukemia through the miR-195/Myb axis

Li, Qun; Wang, Jianmin

doi:10.1039/c9ra04843j

Cited by 13 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In pediatric acute myeloid leukemia (AML), ZFAS1 elevates resistance to Adriamycin (ADR) as a frequent chemotherapeutic. According to studies, ADR promotes ZFAS1 in pediatric AML, and knockdown of ZFAS1 or Myb diminishes ADR resistance in vitro [ 72 ]. ZFAS1 directly interacts with miR-195, which regulates Myb to increase ADR resistance in pediatric AML [ 73 ].…”

Section: The Role Of Zfas1 In Chemoresistancementioning

confidence: 99%

See 1 more Smart Citation

An update on the molecular mechanisms of ZFAS1 as a prognostic, diagnostic, or therapeutic biomarker in cancers

Mehrab Mohseni,

Zamani,

Momeni

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Zinc finger antisense 1 (ZFAS1), a newly discovered long noncoding RNA, is expressed in various tissues and organs and has been introduced an oncogenic gene in human malignancies. In various cancers, ZFAS1 regulates apoptosis, cell proliferation, the cell cycle, migration, translation, rRNA processing, and spliceosomal snRNP assembly; targets signaling cascades; and interacts with transcription factors via binding to key proteins and miRNAs, with conflicting findings on its effect on these processes. ZFAS1 is elevated in different types of cancer, like colorectal, colon, osteosarcoma, and gastric cancer. Considering the ZFAS1 expression pattern, it also has the potential to be a diagnostic or prognostic marker in various cancers. The current review discusses the mode of action of ZFAS1 in various human cancers and its regulation function related to chemoresistance comprehensively, as well as the potential role of ZFAS1 as an effective and noninvasive cancer-specific biomarker in tumor diagnosis, prognosis, and treatment. We expected that the current review could fill the current scientific gaps in the ZFAS1-related cancer causative mechanisms and improve available biomarkers.

show abstract

Section: The Role Of Zfas1 In Chemoresistancementioning

confidence: 99%

“…ZFAS1 directly interacts with miR-195, which regulates Myb to increase ADR resistance in pediatric AML [ 73 ]. Therefore, ZFAS1 may be a diagnostic or therapeutic marker for ADR resistance in pediatric AML [ 72 ].…”

Section: The Role Of Zfas1 In Chemoresistancementioning

confidence: 99%

An update on the molecular mechanisms of ZFAS1 as a prognostic, diagnostic, or therapeutic biomarker in cancers

Mehrab Mohseni,

Zamani,

Momeni

et al. 2024

Discov Onc

View full text Add to dashboard Cite

show abstract

“…The p15 INK4B /p16 INK4A repressor ANRIL was recently suggested to contribute to leukaemia progression by increasing glucose metabolism (Sun et al , ). Additionally, zinc finger antisense 1 ( ZFAS1 ) was shown to mediate doxorubicin resistance in paediatric AML via inhibition of miR‐195 and subsequent upregulation of MYB (Li & Wang, ). Low expression and promoter hypermethylation of MEG3 is associated with poor prognosis in AML, and it was recently shown that mutations in TET2 or WT1 substantially reduce MEG3 levels (Lyu et al , ).…”

Section: Epigenetic Dysregulation In Paediatric Amlmentioning

confidence: 99%

Epigenetics of paediatric acute myeloid leukaemia

2019

View full text Add to dashboard Cite

show abstract

“…Dysregulation of lncRNAs (such as lncRNA CRNDE, KCNQ1OT1, and ZFAS1) is implicated in chemoresistance in AML [10][11][12][13]. Long intergenic non coding RNAs (lincRNAs), a type of lncRNA, are emerging as key regulators in cancer development.…”

Section: Introductionmentioning

confidence: 99%

Silencing LINC00987 ameliorates adriamycin resistance of acute myeloid leukemia via miR-4458/HMGA2 axis

Liu,

Zhu,

Liao

et al. 2024

Biol Direct

View full text Add to dashboard Cite

Background Most patients with acute myeloid leukemia (AML) eventually develop drug resistance, leading to a poor prognosis. Dysregulated long gene non coding RNAs (lincRNAs) have been implicated in chemoresistance in AML. Unfortunately, the effects of lincRNAs which participate in regulating the Adriamycin (ADR) resistance in AML cells remain unclear. Thus, the purpose of this study is to determine LINC00987 function in ADR-resistant AML. Methods In this study, ADR-resistant cells were constructed. LINC00987, miRNAs, and HMGA2 mRNA expression were measured by qRT-PCR. P-GP, BCRP, and HMGA2 protein were measured by Western blot. The proliferation was analyzed by MTS and calculated IC50. Soft agar colony formation assay and TUNEL staining were used to analyze cell colony formation and apoptosis. Xenograft tumor experiment was used to analyze the xenograft tumor growth of ADR-resistant AML. Results We found that higher expression of LINC00987 was observed in AML patients and associated with poor overall survival in AML patients. LINC00987 expression was increased in ADR-resistant AML cells, including ADR/MOLM13 and ADR/HL-60 cells. LINC00987 downregulation reduces ADR resistance in ADR/MOLM13 and ADR/HL-60 cells in vitro and in vivo, while LINC00987 overexpression enhanced ADR resistance in MOLM13 and HL-60 cells. Additionally, LINC00987 functions as a competing endogenous RNA for miR-4458 to affect ADR resistance in ADR/MOLM13 and ADR/HL-60 cells. HMGA2 is a target of miR-4458. LINC00987 knockdown and miR-4458 overexpression reduced HMGA2 expression. HMGA2 overexpression enhanced ADR resistance, which reversed the function of LINC00987 silencing in suppressing ADR resistance of ADR/MOLM13 and ADR/HL-60 cells. Conclusions Downregulation of LINC00987 weakens ADR resistance by releasing miR-4458 to deplete HMGA2 in ADR/MOLM13 and ADR/HL-60. Therefore, LINC00987 may act as the therapeutic target for treating chemoresistant AML.

show abstract

Long noncoding RNA ZFAS1 enhances adriamycin resistance in pediatric acute myeloid leukemia through the miR-195/Myb axis

Abstract: Long noncoding RNA ZFAS1 silencing alleviated ADR resistance of AML cells.

Cited by 13 publications

References 36 publications

An update on the molecular mechanisms of ZFAS1 as a prognostic, diagnostic, or therapeutic biomarker in cancers

An update on the molecular mechanisms of ZFAS1 as a prognostic, diagnostic, or therapeutic biomarker in cancers

Epigenetics of paediatric acute myeloid leukaemia

Silencing LINC00987 ameliorates adriamycin resistance of acute myeloid leukemia via miR-4458/HMGA2 axis

Contact Info

Product

Resources

About